BioCentury | Oct 14, 2015
Financial News

Audentes raises $65 million in series C

...CASQ2 ) to cardiomyocytes to treat catecholaminergic polymorphic ventricular tachycardia (CPVT) in patients with inherited CASQ2...
BioCentury | Oct 5, 2015
Company News

Cadiogen, Audentes Therapeutics deal

...delivers calsequestrin 2 (CASQ2) to cardiomyocytes to treat catecholaminergic polymorphic ventricular tachycardia (CPVT) in patients with inherited CASQ2...
Items per page:
1 - 2 of 2